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Abstract
Background: To assess the relationship between different indications for trans pars plana vitrectomies (PPV’s) and
the intraocular pressure (IOP), and the effect of multiple PPV’s on the IOP. We also examined whether there were
differences in the number of IOP-lowering medications or surgeries before and after PPV.
Methods: A retrospective study including all patients that underwent at least one PPV in the period from 2001 till
2014 at our clinic. Medical records of all patients were reviewed and clinically relevant data were entered in a
database. Generalized estimating equations models for repeated measurements were used to examine the effect of
the number of PPV’s on the IOP and on the risk of undergoing glaucoma surgery, for each of the indications for
PPV.
Results: Of 1072 PPV’s 447 eyes fulfilled the inclusion criteria. The IOP increased with 3.0 mmHg after a PPV with
indication retinal detachment (p < 0.001), but remained stable after PPV for epiretinal membrane (p = 0.555), macular
hole (p = 0.695), and vitreous hemorrhage (p = 0.787). At the end of the follow-up period the number of IOP-
lowering medications was significantly higher compared to baseline, except in the macular hole group (p = 0.103).
Also, the number of eyes that underwent glaucoma surgery was significantly higher compared to the fellow (not-
operated) eyes (p < 0.001). There was a significant association between the number of PPV’s and the final IOP for
the indication retinal detachment (p = 0.009), and between the number of PPV’s and glaucoma surgery (odds ratio
[95% confidence interval]: 2.60 [1.62–4.15]).
Conclusions: The IOP rises significantly after PPV with indication retinal detachment. This association was not
found for other indications for PPV. Also, the risk of IOP-lowering surgeries was higher after PPV, but not different
between the PPV indications. The IOP should be monitored carefully after PPV, since there may be a higher risk of
secondary glaucoma.
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Background
The introduction of pars plana vitrectomy (PPV) has led
to a great advancement in treating conditions of the pos-
terior segment of the eye. [1, 2] Over the years the num-
ber of indications for PPV’s has increased including
retinal detachment, [3, 4] epiretinal membrane, [5]
macular hole, [6] vitreous hemorrhage, [7, 8] floaters, [9]
and vitreomacular traction syndrome. [10] Even though
PPV has become indispensable in the treatment of many
eye diseases, there are still some serious complications
that can occur postoperatively. One of them is an
elevated intraocular pressure (IOP), which is a major risk
factor of glaucoma: an optic neuropathy that causes irre-
versible progressive visual field loss. Numerous studies
have evaluated the postoperative effects of PPV on the
IOP. In the early postoperative period an elevation of 5–
35% of the IOP has been observed. [11, 12] On the late
postoperative effects there have been conflicting results.
[13–18] Some studies reported an increase in the IOP or
the number of IOP-lowering medications after PPV, [13,
14] with some suggesting that the IOP-increase may be
affected by the indication for the PPV. [15] Several other
studies could not observe an increase in IOP after vi-
trectomy. [16–18]
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Although many studies have described the influence of
PPV on IOP, the influence of the indication and the
number of PPV’s on the long-term IOP has not yet been
clarified even though repeated PPV’s are not uncommon.
The aim of the present study was first to assess the rela-
tionship between the most common indications for a
PPV and the IOP. Secondly, we examined whether there
were differences in the number of IOP-lowering medica-
tions or surgeries before and after PPV. Thirdly, we
assessed whether the number of PPV’s was associated
with a higher IOP or a higher risk of undergoing glau-
coma surgery.
Methods
Study population
For this retrospective study we selected all patients that
underwent at least one PPV in the period from October
2001 till September 2014 at the department of Ophthal-
mology of the Erasmus University Medical Center, Rot-
terdam, the Netherlands.
The medical records of all patients were reviewed and
clinically relevant data were entered in a database. Data
of the last preoperative visit, postoperative follow-up
data at 1 day, < 2 weeks, 1–3 months, 1 year, and > 3 years
(last visit) were collected. The following pre- and post-
operative data were recorded: age, gender, visual acuity,
refraction, intraocular lens status, axial length, IOP, and
use of ophthalmic medication. Peroperative data con-
sisted of: date of surgery, operated eye, indication, ap-
plied tamponade, usage of argon laser, and gauge of
vitrectomy device.
The following indications for PPV were included: ret-
inal detachment, epiretinal membrane, macular hole,
and vitreous hemorrhage. Exclusion criteria included:
eye trauma, intraocular tumor, scleral buckling proced-
ure, endophthalmitis, suprachoroidal hemorrhage, treat-
ment because of previous performed complicated
cataract surgery (such as intraocular lens luxation, pos-
terior capsule defect with vitreous loss, or retained lens
material), neovascular glaucoma, uveitis with vitritis, and
vitreous biopsy.
IOP measurement, PPV surgery and follow-up
The IOP was measured at each visit using Goldmann
applanation tonometry (Haag-Streit, Köniz, Switzerland).
The device had been calibrated conform manufacturers
standards. The number of IOP-lowering medications
was calculated by adding the number of different cat-
egories of medication. The categories were: beta-
blockers, prostaglandin-analogues, carbonic anhydrase
inhibitors, alfa2-agonists, and oral acetazolamide. Fixed
combinations of eye drops were calculated as two separ-
ate drugs.
The PPV was performed by one of three experienced
surgeons. The surgical procedure consisted of a 20, 23
or 25-gauge PPV with or without additional argon laser
coagulation. Applied tamponade included: air, gas, or
silicone oil. Details on the surgical procedures are de-
scribed elsewhere. [19]
Follow-up time was measured as the difference be-
tween the last preoperative visit for the first PPV till the
last visit. If the PPV in the timeframe (from October
2001 till September 2014) was not the first PPV of the
patient, we reviewed the medical records again to find
out when the patient underwent the first PPV (i.e. before
October 2001).
Statistical analysis
The effect of peroperative variables were assessed using
ANOVA-tests, chi-square and, if the number of cases in
a subgroup analysis was too low, Fisher’s exact tests. The
following groups were made according to PPV indica-
tions: retinal detachment, epiretinal membrane, macular
hole, and vitreous hemorrhage. To remove the possible
effect of differences in baseline characteristics between
the different groups on the IOP, we analyzed each PPV
indication separately. If a patient used IOP-lowering
medication at a visit or had a history of IOP-lowering
laser in the included eye(s), we recalculated the IOP of
that visit. This was to be able to compare untreated
IOP-levels with treated IOP-levels. Based on a reported
average of a 30% reduction in IOP caused by IOP lower-
ing medication, reported in a meta-analysis of random-
ized clinical trials, IOP values of those receiving
medication were divided by 0.7 to estimate the untreated
IOP. [20, 21] Patients that underwent surgery for glau-
coma were excluded from this analysis. A subset com-
parison was performed to analyze the differences
between the operated and non-operated fellow eyes
using paired t-tests.
In some cases both eyes of a patient were included. To
account for the within-patient inter-eye correlations gen-
eralized estimating equations were applied. General lin-
ear mixed models for repeated measurements were used
to examine the effect of the number of PPV’s on the
IOP for each of the PPV indications. An unstructured
correlation matrix was applied for the models. These
models were adjusted for age, gender, axial length, and
follow-up time. No adjustment was done for the lens
status, because cataract surgery may be performed be-
fore or during the study. Furthermore, previously we did
not find a significant difference in IOP if measured with
Goldmann applanation tonometry between PPV and
PPV combined with cataract surgery. [19] Similar ana-
lyses were performed to calculate odds ratios (ORs) with
corresponding 95% confidence intervals (CIs) for the ef-
fect of the number of PPV’s on the risk of requiring
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glaucoma surgery. These analyses were adjusted for the
above-mentioned variables and were done separately for
each of the PPV indications (if possible). All statistical
analyses were performed using SPSS v22.0 for Windows
(SPSS Inc., Chicago, IL, USA). A p-value of < 0.05 was
considered statistically significant.
The datasets used and/or analyzed during the current
study are available from the corresponding author on
reasonable request.
Results
A total of 1072 PPV’s were performed in 615 patients.
Of these, 409 patients (447 eyes) fulfilled the inclusion
criteria. Table 1 presents the (preoperative) general char-
acteristics of the study population according to PPV in-
dication. The mean (median; range) follow-up was 2.6
(1.5; 0.1–17.4) years. None of the patients had a history
of glaucoma surgery before they underwent PPV. The
distribution of type of tamponade for the different PPV
indications is presented in Table 2.
Concerning the peroperative variables, no association
was observed between the final IOP and the type of tam-
ponade (p = 0.752) and usage of argon laser or retinal
cryocoagulation (p = 0.218). Although patients who
underwent PPV using a 20-gauge had a higher final IOP
compared to those who underwent a 23 or 25-gauge
PPV, this difference was not significant (20.5 mmHg,
15.4 mmHg, and 15.5 mmHg, respectively; p = 0.073).
Table 3 displays the differences in the baseline and the
final IOP for the operated and non-operated eyes for
each PPV indication. The IOP increased with 3.0 mmHg
after PPV with indication retinal detachment (p < 0.001),
but remained stable after PPV for the other indications.
In the non-operated eyes no significant increase in base-
line and final IOP was found for the different PPV
indications. The axial length and IOL-status showed no
significant correlation to either baseline IOP or final
IOP, in both operated and non-operated eyes. Table 4
shows the number of IOP-lowering medications for the
different PPV indications. Of the eyes that underwent
PPV for retinal detachment, 14 eyes required IOP-lower-
ing medication using a total of 25 IOP-lowering medica-
tions. At the end of the follow-up period the total
number IOP-lowering medications was higher than at
baseline (p < 0.001, p = 0.034, p = 0.103, and p = 0.034 for
the PPV indications retinal detachment, epiretinal mem-
brane, macular hole, and vitreous hemorrhage, respect-
ively). A total of 11 patients underwent glaucoma
surgery compared to 0 at baseline. Surgery consisted of
glaucoma drainage device (N = 7 eyes), trabeculectomy
(N = 2 eyes), surgical peripheral iridectomy (N = 1 eye),
and one patient underwent trabeculectomy followed by
a glaucoma drainage device (N = 1 eye). After exclusion
of the eyes that underwent glaucoma surgery after PPV,
IOP was still significantly higher compared with baseline
(p < 0.001). During the follow-up period no surgeries for
glaucoma were performed in the non-operated fellow
eyes.
The average number of PPV’s was 2.8 (range 1–10).
The multivariate analyses showed a significant associ-
ation between the number of PPV’s and the final IOP for
the indication retinal detachment (1.11 mmHg decrease
in IOP per PPV; p = 0.009). Patients who underwent
more than five PPV’s for the indication retinal detach-
ment more often suffered from hypotony compared to
those who underwent a fewer number of PPV’s. This as-
sociation was not present for the indications epiretinal
membrane (p = 0.168), macular hole (p = 0.573), and vit-
reous hemorrhage (p = 0.921). Regarding glaucoma sur-
gery, for each performed PPV the risk of undergoing
Table 1 General (preoperative) characteristics of the study eyes according to PPV indication, presented as mean ± s.d. unless stated
otherwise
PPV indication Retinal detachment (N =
139)
Epiretinal membrane (N =
124)
Macular hole (N =
72)
Vitreous hemorrhage (N =
112)
Age (years) 69.6 ± 11.0 74.7 ± 7.7 72.5 ± 8.5 70.6 ± 11.8
Women, N (%) 51 (36.7) 71 (57.3) 51 (70.8) 56 (50.0)
Best visual acuity 0.3 ± 0.4 0.5 ± 0.2 0.3 ± 0.2 0.2 ± 0.4
Baseline IOP (mmHg) 14.2 ± 4.9 14.5 ± 3.6 15.2 ± 4.7 14.9 ± 6.5
Baseline use of IOP-lowering Rx, N
(%)
1 (0.7) 0 (0.0) 0 (0.0) 1 (0.9)
Pseudophakic eyes, N (%) 33 (23.7) 45 (36.3) 22 (30.6) 51 (45.5)
Axial length (mm) 24.9 ± 1.6 23.9 ± 1.5 23.9 ± 1.9 23.6 ± 1.3
History of diabetic mellitus, N (%) 13 (9.4) 22 (17.7) 8 (11.1) 50 (44.6)
History of diabetic retinopathy, N
(%)
3 (2.2) 4 (3.2) 1 (1.4) 21 (18.8)
History of hypertension, N (%) 13 (9.4) 27 (21.8) 15 (20.8) 24 (21.4)
PPV pars plana vitrectomys.d. standard deviation, IOP intraocular pressure, Rx ophthalmic medication
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glaucoma surgery increased 2.60 fold (95% CI: 1.62–
4.15), especially for the indication retinal detachment
(OR: 4.60 [95% CI: 1.54–13.75]). For the other PPV indi-
cations the number of glaucoma surgeries was too low
to perform subgroup analyses.
Discussion
The current study shows that among the most common
PPV indications patients who underwent PPV because
of retinal detachment had a significantly higher IOP
postoperatively compared to the preoperative IOP. Com-
pared to the non-operated eyes, glaucoma surgery was
performed more often on eyes that had undergone a
PPV. Also the risk of undergoing glaucoma surgery in-
creased with the number of PPV’s.
Since elevated IOP plays a crucial role in the develop-
ment of glaucoma, it is important for clinicians to know
the effect of a PPV on the IOP. Patients with or suspect
for glaucoma are more prone to develop a higher IOP in
the first month postoperative compared to patients not
suspect for glaucoma. [22] As mentioned in the Intro-
duction in the early postoperative period, less than 72 h
after PPV, an elevation of 5–35% of the IOP has been re-
ported. [11, 12] This rise in IOP is probably due to post-
operative inflammation, effects of the steroids, or a
reaction to the peroperative tamponade used. Concern-
ing the peroperative variables, on one hand some studies
reported an increased IOP after PPV with expanding gas
or silicon oil tamponade, [23–29] while on the other
hand silicone oil tamponade did not appear to be associ-
ated with persisting high IOP or progressive optic disc
changes 48months after PPV. [30] A reason that the
present study could not confirm an association might be
the size of different subgroups of tamponades. Almost
50% of all tamponades consisted of SF6-gas. Due to this
the size of the other subgroups of tamponade were
small. Furthermore, the use of silicone oil as tamponade
is often not a first choice, but is usually performed after
a first PPV fails to be successful. As expected peropera-
tive argon laser or retinal cryocoagulation did not affect
the IOP. This finding is in line with another study. [22]
Although, one study reported an association between
the IOP 1 day after PPV and the number of laser photo-
coagulations, [31] this effect is likely not to persist on
the long-term IOP. Regarding the applied gauge PPV, it
has been suggested that a smaller sclerotomy in the pars
plana of the eye, i.e. a higher gauge, may result in more
hypotony early post-operative after PPV. [32] This is ex-
plained by the fact that the sclerotomy in a 23 or higher
gauge PPV are not sutured like in a 20-gauge PPV pro-
cedure resulting in more wound leakage. The hypotony
usually resolves spontaneously once the sclerotomies
heal adequately. In the present study the post-operative
IOP was found to be higher for 20-gauge PPV compared
Table 2 Peroperative used tamponade of the study eyes according to PPV indication, presented as number (percentage)
PPV indication Retinal detachment (N = 139) Epiretinal membrane (N = 124) Macular hole (N = 72) Vitreous hemorrhage (N = 112)
Tamponade, N (%)
Air 15 (10.8) 100 (80.6) 2 (2.8) 100 (89.3)
SF6-gas 93 (66.9) 23 (18.5) 62 (86.1) 11 (9.8)
Other gas (e.g., C3F8) 10 (7.2) 1 (0.8) 5 (6.9) 0 (0.0)
Silicone oil 21 (15.1) 0 (0.0) 3 (4.2) 1 (0.9)
PPV pars plana vitrectomy, SF6 sulfurhexafluoride, C3F8 perfluoropropane
Table 3 Mean IOP of the study eyes according to PPV indication, presented as mean ± s.d. unless stated otherwise
PPV
indication
Retinal detachment (N =
139)
Epiretinal membrane (N =
124)
Macular hole (N =
72)
Vitreous hemorrhage (N =
112)
Operated eyes
Preoperative Baseline IOP
(mmHg)
14.2 ± 4.9 14.5 ± 3.6 15.2 ± 4.7 14.9 ± 6.5
Postoperative Final IOP (mmHg) 17.2 ± 9.4 14.7 ± 4.3 15.5 ± 4.9 15.0 ± 7.0
p-value < 0.001 0.555 0.695 0.787
Non-operated fellow eyesa
(N = 96) (N = 94) (N = 52) (N = 69)
Preoperative Baseline IOP
(mmHg)
15.5 ± 5.9 15.6 ± 3.1 15.2 ± 3.1 15.7 ± 4.9
Postoperative Final IOP (mmHg) 16.1 ± 5.0 15.2 ± 3.7 15.9 ± 5.2 14.5 ± 4.1
p-value 0.092 0.272 0.300 0.023
a patients who underwent PPV on both eyes were excluded, PPV pars plana vitrectomy, s.d. standard deviation; IOP intraocular pressure
Kovacic et al. BMC Ophthalmology          (2019) 19:175 Page 4 of 7
to 23 or 25-gauge PPV, though not statistically
significant.
Regarding the late postoperative period, multiple stud-
ies assessed the effect of a PPV on the IOP. Chang found
that a PPV could increase the risk of the development of
glaucoma in up to 15–20% of the eyes that are operated.
He theorized that oxidative stress affects the cells of the
trabecular meshwork, causing a rise in IOP. [13] Wu et
al. reported a significant increase in the number of
vitrectomized eyes (19.2%) with an IOP ≥ 24mmHg or a
rise in IOP ≥ 5 mmHg, compared to non-operated fellow
eyes (4.5%). [14] Fujikawa et al. reported a mean increase
in IOP of 0.7 mmHg after PPV for macular hole, which
was significantly higher than the 0.3 mmHg increase
after PPV for epiretinal membrane. [15] On the contrary,
Mi et al. found no significant increase in IOP after PPV
for epiretinal membrane or macular hole in eyes without
pre-existing glaucoma. [16] Yu et al. compared vitrecto-
mized eyes with fellow control eyes in 441 patients and
found no significant differences in mean IOP or in the
development of glaucoma. [17] Lalezary et al. researched
101 eyes after elective PPV. They found no significant
increase in IOP of > 4 mmHg in operated versus non-op-
erated eyes. [18] The present study found a significant
increase in IOP of 3.0 mmHg (21.1%) after PPV with in-
dication retinal detachment, however not after PPV for
epiretinal membrane (0.2 mmHg), macular hole (0.3
mmHg) and vitreous hemorrhage (0.1 mmHg). This dif-
ference might be caused by synechial angle closure (par-
tial or significant), though no gonioscopy was performed
to confirm this.
Little is known about the effects of multiple PPV’s on
the IOP. We observed a significant association between
the number of PPV’s and the final IOP for the indication
retinal detachment, though not for the other indications.
This is in line with a study on 70 eyes by Tranos et al.
[30] They reported a mean of two PPV’s for retinal de-
tachment to be a risk factor for developing progressive
optic disc changes. Nevertheless, the significance disap-
peared when adjusting for the 9% that developed a hy-
potony. Furthermore, they did not assess other
indications for PPV. [30] We found a significant
decrease in IOP after multiple PPV’s for retinal detach-
ment. However, after excluding the 6 eyes that developed
hypotony (IOP ≤ 4 mmHg), the significant effect disap-
peared. These were all eyes that underwent multiple
PPV’s. Only a few eyes can change this effect on IOP.
Thus the IOP rises after PPV for retinal detachment, but
probably the effect of the number of PPV’s on the final
IOP is not much. The significantly lower IOP may also
be explained by the fact that multiple PPV’s result in
dysfunction of the ciliary body caused by the removal of
proliferative vitreous membranes that cover the ciliary
body. Furthermore, it is very difficult to estimate the un-
treated IOP after glaucoma surgery, and as a conse-
quence, patients who underwent glaucoma surgery were
excluded from the analyses in which the final IOP was
entered as the outcome. Thus the eyes that developed a
hypotony and the exclusion of eyes that underwent glau-
coma surgery might explain the present IOP-lowering
effect of multiple PPV’s. Inclusion of eyes that under-
went glaucoma surgery showed a strong association be-
tween the number of PPV’s and the risk of undergoing
glaucoma surgery (OR: 2.60 [95% CI: 1.62–4.15]). These
results are in line with another recent study (OR 2.35
[95% CI: 1.17–4.70]). [33]
Since treatment of IOP is the keystone in preventing
and managing glaucoma, we also looked at IOP-lowering
interventions, such as medication and surgery. At base-
line only 2 eyes (0.4%) were on IOP-lowering medica-
tion, which increased to 27 eyes (6.0%) at the end of
follow-up, though not statistically significant (p = 0.117).
Chang also reported an increase in the number of IOP-
lowering medication in vitrectomized eyes compared
with the fellow control eyes (1.79 vs. 0.65, respectively).
[13] To limit the effect of other attributing factors like
time-lag, we did a paired subset comparison with the
non-operated eyes. It showed that in the non-operated
eyes no glaucoma surgery was performed during follow-
up. This observation shows that the effects of PPV are
not only limited to a rise in IOP, but also have a clinical
impact where glaucoma surgery is needed. Nonetheless,
it should be emphasized that treatment of IOP does not
necessarily mean that a person suffers from glaucoma,
Table 4 Postoperative characteristics of the study eyes according to PPV indication, presented as mean ± s.d. unless stated
otherwise
PPV indication Retinal detachment (N =
139)
Epiretinal membrane (N =
124)
Macular hole (N =
72)
Vitreous hemorrhage (N =
112)
Use of IOP-lowering Rx, N eyes
(%)
14 (10.1) 5 (4.0) 3 (4.2) 5 (4.5)
Total N of IOP-lowering Rxa 25 7 4 12
Follow-up, median (IQR; months) 17.3 (3.8–49.5) 16.0 (5.6–36.1) 18.3 (7.4–33.4) 25.8 (5.7–47.9)
Number of PPV 2.6 ± 1.9 1.6 ± 0.9 2.0 ± 1.2 1.9 ± 1.1
PPV pars plana vitrectomy, s.d. standard deviation, IOP intraocular pressure, Rx ophthalmic medication, IQR interquartile range, a cumulative number of different
categories of IOP lowering Rx: beta-blockers, prostaglandins, carbonanhydrase inhibitor, alfa-agonists, and oral acetazolamide
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but he/she has an increased risk to develop glaucoma.
From an ethical point of view it is not possible to screen
someone for glaucoma if the person requires a PPV for
retinal detachment or a vitreous hemorrhage. Moreover,
monitoring glaucoma using visual field progression has
been proven to be a difficult task and visual field defects
can also occur after retinal detachment. Therefore, we
only focused on IOP and IOP-lowering treatment (either
with medication or surgery) instead of a diagnosis of
glaucoma. Besides, in many cases follow-up was too
short (57.7% had a follow-up < 2 years) to detect glau-
comatous damage at the optic nerve or visual field loss
(see further).
Due to its retrospective design the current study has a
few limitations. First, the follow-up of patients was lim-
ited in patients who had no complaints postoperatively.
These patients might have developed an unnoticed high
IOP. However, the non-inclusion of these patients would
have resulted in an underestimation of our findings. Sec-
ondly, the probability of finding an increase in IOP is
higher in eyes with retinal detachments (compared to
the other indications), because they often have a lower
pre-operative IOP than healthy eyes. Furthermore, re-
current retinal detachments are not uncommon and
may result in multiple PPV’s. Thirdly, inclusion of eyes
with diabetes mellitus might be a confounding factor in
the present study, however, excluding these eyes did not
affect the results. Finally, after the shift from 20-gauge to
higher gauge PPV’s, complex eyes were mostly still oper-
ated using 20-gauge PPV, which might affect its associ-
ation with the final IOP.
Conclusion
The current study showed an increase in IOP after PPV
with indication retinal detachment, while this effect was
absent in the other indications for PPV. Furthermore, it
showed that eyes undergoing one or more PPV’s have an
almost three-fold higher risk of undergoing glaucoma
surgery compared to their fellow eyes. Careful monitor-
ing of the IOP is needed after PPV, especially in case of
retinal detachment, to prevent and manage secondary
glaucoma.
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